Observational Study on the Clinical Profile of Patients With Uncontrolled Severe Asthma Treated With Tezepelumab in Italy
← catalyst calendarNCT06948396 · readout in 284 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
315actual
Sites
28
Country
Italy
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-25 | actual | When the study began enrolling |
| Primary completion | 2027-05-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-05-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-04-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Asthma
Intervention
- Biological: Tezepelumab
Primary outcomes
what the primary-completion date above is the date OFDemographic and Clinic characterization
measured Basal
COMORBIDITIES AND RELEVANT MEDICAL HISTORY
measured Basal
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed